期刊
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
卷 234, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.jpba.2023.115541
关键词
Capillary electrophoresis-mass spectrometry; Monoclonal antibodies; Biological sample; Post-translational modifications; Biosimilar; Kinetic study
Despite the challenges in predicting and monitoring post-administration effects of post-translational modifications, this study identified and evaluated the modification kinetics of infliximab and its biosimilars in vitro. The methodology used mass spectrometry analysis to determine modified and unmodified forms, and the results showed the potential for studying structural stability after administration.
Despite reports indicating the potential impact of post-translational modifications on the activity of a monoclonal antibody, their prediction or monitoring post-administration remains a challenge. In addition, with the expiration of patents concerning the early generation of mAbs, the production of biosimilars is constantly increasing. Structural differences of biosimilars compared to the innovator product are commonly evaluated for the formulated product in the context of biosimilarity assessment. However, estimating their structural outcome after administration is particularly difficult. Due to the complexity of in vivo studies, there is a need to develop analytical strategies to predict PTMs consequently to their administration and their impact on mAbs potency. Here, we identified and evaluated the modification kinetics of 4 asparagine deamidations and 2 aspartate isomerizations of infliximab innovator product (Remicade (R)) and two biosimilars (Inflectra (R) and Remsima (R)) in vitro using serum incubation at 37 degrees C. The methodology was based on a bottom-up approach with capillary electrophoresis hyphenated with mass spectrometry analysis for an unequivocal assignment of modified and unmodified forms. 2 asparagines demonstrated a gradual deamidation correlated with incubation time. The specific extraction efficiency was evaluated to determine possible changes in the antigen binding affinity of infliximab with the incubation. Results showed the possibility to achieve an additional aspect concerning bio-similarity assessment, oriented on the study of the structural stability after administration.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据